Stonepine Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Stonepine Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$974K	Buy	+50,000	New	+$906K	0.55%	43

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Stonepine Capital Management's MLTX Position: Q2 2026 in Review

Stonepine Capital Management opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 50,000 shares worth $974K. The stake represents 0.55% of the portfolio and ranks #43 among its holdings.

173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Stonepine Capital Management held 50,000 shares of MoonLake Immunotherapeutics worth $974K as of Q2 2026.
MoonLake Immunotherapeutics was a new Stonepine Capital Management position in Q2 2026.
MoonLake Immunotherapeutics made up 0.55% of Stonepine Capital Management's portfolio in Q2 2026, its #43 holding.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.